Stoke Therapeutics, Inc. (STOK): Price and Financial Metrics


Stoke Therapeutics, Inc. (STOK)

Today's Latest Price: $46.89 USD

0.87 (1.89%)

Updated Dec 3 11:50am

Add STOK to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

STOK Stock Price Chart Interactive Chart >

Price chart for STOK

STOK Price/Volume Stats

Current price $46.89 52-week high $53.82
Prev. close $46.02 52-week low $15.82
Day low $45.55 Volume 23,881
Day high $48.97 Avg. volume 151,916
50-day MA $40.65 Dividend yield N/A
200-day MA $29.13 Market Cap 1.57B

Stoke Therapeutics, Inc. (STOK) Company Bio


Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.


STOK Latest News Stream


Event/Time News Detail
Loading, please wait...

STOK Latest Social Stream


Loading social stream, please wait...

View Full STOK Social Stream

Latest STOK News From Around the Web

Below are the latest news stories about Stoke Therapeutics Inc that investors may wish to consider to help them evaluate STOK as an investment opportunity.

The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ...

Benzinga | September 15, 2020

Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 9:20 a.m. ET. A live webcast of the presentation will be available on the Investors & Media section of Stoke’s we

Business Wire | September 9, 2020

Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Garry E. Menzel, Ph.D., to both its Board of Directors and Compensation Committee. “Garry brings more than 25 years of executive management experience in the global healthcare sector, including senior leadership roles at TCR2 Therapeutics, DaVita H

Business Wire | August 17, 2020

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2020 and provided business updates. “Today we are announcing that the first patient has been dosed with STK-001, which we believe has the potential to be the first-disease modifying medicine for Dravet syndrome, a severe and

Business Wire | August 10, 2020

Stoke Therapeutics to Present at Upcoming Investor Conferences in August

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that members of management will present at three upcoming investor conferences in August: 2020 Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 11, 2020 Time: 11:30 a.m. ET BTIG Virtual Biotechnology Conference Date: Tuesday, August 11, 2020 Time:

Business Wire | August 4, 2020

Read More 'STOK' Stories Here

STOK Price Returns

1-mo 18.35%
3-mo 62.93%
6-mo 90.22%
1-year 85.92%
3-year N/A
5-year N/A
YTD 65.57%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6942 seconds.